Wounds and Injuries

All Conditions

Neoplasms

Fractures, Bone

Abdominal Neoplasms

Rib Fractures

Thoracic Neoplasms

Thoracic Injuries

Anti-Arrhythmia Agents

Channel Blockers

Central Nervous System Depressants

All Drugs and Chemicals

Pharmaceutical Solutions

Herbal and Botanical

Lidocaine

Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures who will have placed a thoracic epidural catheter to manage their perioperative analgesia.

With an US-guided parasagittal oblique approach, the interlaminar space at the union between laminas and spinous processes at the predefined insertion level will be identified. A skin wheal will be raised with 3 mL of lidocaine 1%. Afterward, an 18-gauge Tuohy epidural block needle will be advanced under direct US vision until the tip is insinuated between the laminas and anchored to the flavum ligament. Then the needle will be attached to a low resistance syringe prefilled with saline solution and advanced until LOR to injection is confirmed. Then a 20-Gauge epidural catheter will be inserted 3-5 cm beyond the needle tip inside the epidural space and the needle removed.

Real-time ultrasound guidance for thoracic epidural catheter placement.

Julián Aliste, MD

Various modalities have been proposed for real-time confirmation of loss of resistance (LOR) for thoracic epidural blocks. With real-time ultrasound (US) guidance, the anesthesiologist attempts to visualize the sonographic advancement of the epidural needle and penetration of the epidural space (as detected by LOR)

This observational study is set out to confirm the reliability of real-time ultrasound guidance as an adjunct to LOR for thoracic epidural blocks.

Real-time Ultrasound Guidance for Thoracic Epidural Blocks

Reliability of Real-time Ultrasound Guidance as an Adjunct to Loss of Resistance for Thoracic Epidural Blocks

After fifteen minutes of local anesthetic administration (4- mL dose of lidocaine 2% with epinephrine 5 μg/mL ), an investigator will apply ice to the T1 to L4 dermatomes bilaterally. The criterion standard for success will be the presence of an epidural block, defined as a block to ice in at least 2 dermatomes bilaterally. If operators could not advance the catheter past the needle tip after 2 attempts despite a 180-degree rotation of the bevel between the first and second attempts, epidural blocks will be considered failures.

Number of blocked dermatomes after injection of local anesthetics through the epidural catheter.

Localization of blocked dermatomes after injection of local anesthetics through the epidural catheter.

Needed time (minutes and seconds) to obtain an adequate image of the interlaminar space

Needed time (minutes and seconds) to insert the Tuohy needle tip in the interlaminar space and confirm a loss of resistance

Elapsed time (minutes and seconds) from loss of resistance acquisition until the catheter is secured

Time (minutes and seconds) between skin disinfection and once the catheter is secured in place.

Incidence of adverse events related to epidural block or local anesthetic injection (i.e. paresthesia, accidental dural puncture, intravascular or subarachnoid position of catheters, intravascular, subarachnoid or subdural injection, local anesthetic systemic toxicity)

University of Chile

Assistant Professor

patients in this group are treated with 3000 cGy in 10 daily fraction

patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)

standard treatment

1800 cGy in 4 fractions administered twice a day

short course treatment

Alessio G Morganti, MD

Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic abdominal malignant lesions

Standard treatment for abdomen lesions (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (1800 cGy in 4 fractions of 450 cGy twice a day) to demonstrate non-inferiority of this scheme

Short Course Radiation Therapy in Palliative Treatment of Abdominal Cancer

SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Abdominal Cancer: an Interventional, Randomized, Multicentric Study

Reduction of initial symptoms after radiotherapy, assessed with Likert scale (bleeding, nausea or vomiting, diarrhea, malnutrition, jaundice, weight loss, bowel obstruction are evaluated as none-mild-moderate-severe)

incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria

incidence of treatment-related adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema

changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Professor

Skin and Connective Tissue Diseases

Rare Diseases

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

Nivolumab

Pembrolizumab

Immunomodulating Agents

Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.

Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.

Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.

Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.

compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.

Chemotherapy

Xiaochun Zhang, Dr

Man Jiang, Dr

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）

Real World Study of Four PD-1 Agents in China

Real World Study of Immunotherapy-Comparison of Four PD-1 Agents in China

PFS was defined as the time from the first day of study treatment to the first documented disease progression per irRC or death due to any cause, whichever occurred first.

ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters). The percentage of strongly PD-L1 positive participants who experienced a CR or PR is presented.

Adverse events are defined as any adverse medical events that occur in the participants taking the drugs and do not necessarily have a causal relationship with the treatment.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Real-time Ultrasound Guidance for Thoracic Epidural Blocks	NCT05165498	Analgesia Thoracic Tumors Abdomen Tumors Rib Fractures	Real-time ultra...	18 Years - 80 Years	University of Chile
Real-time Ultrasound Guidance for Thoracic Epidural Blocks	NCT05165498	Analgesia Thoracic Tumors Abdomen Tumors Rib Fractures	Real-time ultra...	18 Years - 80 Years	University of Chile
Short Course Radiation Therapy in Palliative Treatment of Abdominal Cancer	NCT03775005	Abdomen Tumors Radiotherapy Palliative Care	standard treatm... short course tr...	18 Years -	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Real World Study of Four PD-1 Agents in China	NCT03966456	Thoracic Cancer Gynecologic Can... Abdomen Tumors Malignant Melan...	Chemotherapy	18 Years - 90 Years	The Affiliated Hospital of Qingdao University

Spots Global Cancer Trial Database for abdomen tumors